Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jakob Haldrup

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Scientific Reports|June 3, 2023
Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screeningJakob Haldrup, Simone Weiss, Linnéa Schmidt, et al.
Frontiers in Genome Editing|December 6, 2021
piggyPrime: High-Efficacy Prime Editing in Human Cells Using piggyBac-Based DNA TranspositionJonas Holst Wolff, Jakob Haldrup, Emil Aagaard Thomsen, et al.
Nucleic Acids Research|June 1, 2021
pegIT - a web-based design tool for prime editingMads Valdemar Anderson, Jakob Haldrup, Emil Aagaard Thomsen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 9, 2022
A truncated reverse transcriptase enhances prime editing by split AAV vectorsZongliang Gao, Sujan Ravendran, Nanna S Mikkelsen, et al.
Oncogene|March 6, 2021
In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit JunMaria Riedel, Martin F Berthelsen, Huiqiang Cai, et al.
Oncogene|November 29, 2020
FRMD6 has tumor suppressor functions in prostate cancerJakob Haldrup, Siri H Strand, Clara Cieza-Borrella, et al.
Nucleic Acids Research|September 7, 2023
Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modificationJakob Haldrup, Sofie Andersen, Alexander Rafael LaVilla Labial, et al.
Oncogene|August 6, 2022
A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancerMalene Blond Ipsen, Ea Marie Givskov Sørensen, Emil Aagaard Thomsen, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Scientific Reports|June 3, 2023
Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screeningJakob Haldrup, Simone Weiss, Linnéa Schmidt, et al.
Frontiers in Genome Editing|December 6, 2021
piggyPrime: High-Efficacy Prime Editing in Human Cells Using piggyBac-Based DNA TranspositionJonas Holst Wolff, Jakob Haldrup, Emil Aagaard Thomsen, et al.
Nucleic Acids Research|June 1, 2021
pegIT - a web-based design tool for prime editingMads Valdemar Anderson, Jakob Haldrup, Emil Aagaard Thomsen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 9, 2022
A truncated reverse transcriptase enhances prime editing by split AAV vectorsZongliang Gao, Sujan Ravendran, Nanna S Mikkelsen, et al.
Oncogene|March 6, 2021
In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit JunMaria Riedel, Martin F Berthelsen, Huiqiang Cai, et al.
Oncogene|November 29, 2020
FRMD6 has tumor suppressor functions in prostate cancerJakob Haldrup, Siri H Strand, Clara Cieza-Borrella, et al.
Nucleic Acids Research|September 7, 2023
Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modificationJakob Haldrup, Sofie Andersen, Alexander Rafael LaVilla Labial, et al.
Oncogene|August 6, 2022
A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancerMalene Blond Ipsen, Ea Marie Givskov Sørensen, Emil Aagaard Thomsen, et al.
Pageof 1